Who is sponsoring NCT07377968?

NCT07377968 is sponsored by Ramathibodi Hospital.

What drugs are being tested in NCT07377968?

Interventions in NCT07377968: garmin vivoactive 5 with self-monitoring data, Garmin vivoactive 5 without self-monitoring data.

What condition does NCT07377968 study?

NCT07377968 studies Obstructive Sleep Apnea (OSA).

Is NCT07377968 still recruiting?

NCT07377968 is currently not yet recruiting. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT07377968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wearable Device to Promote CPAP Adherence in Obstructive Sleep Apnea (OSA) Patients

Not yet recruiting NA Last updated 30 January 2026

What this trial tests

NA trial testing garmin vivoactive 5 with self-monitoring data in Obstructive Sleep Apnea (OSA) in 80 participants. Not yet recruiting.

Timeline

6 January 2026

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Ramathibodi Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	80
Start date	6 January 2026
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across Thailand

Drugs / interventions tested

garmin vivoactive 5 with self-monitoring data
Garmin vivoactive 5 without self-monitoring data

Conditions studied

Obstructive Sleep Apnea (OSA) — all drugs for Obstructive Sleep Apnea (OSA) →

Sponsor

Ramathibodi Hospital

Who can join

19 and older, any sex, with Obstructive Sleep Apnea (OSA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study type: clinical trial is to evaluate adherence for CPAP used with wearable device in OSA patients comparing with controlled group; could include any of the following: adult patients (≥ 19 yr of age) with moderate to severe OSA (AHI ≥ 15 events/hr by polysomnography (PSG), according to the American Academy of Sleep Medicine, diagnosed at the sleep clinic in Ramathibodi hospital, patients with OSA who are first time to prescribed CPAP treatment and in the waiting process for their machine. The main question it aims to answer is: Could a wearable device help increase the adherence of CPAP in obstructive sleep apnea patients? Primary outcome is adherence for CPAP: time usage per day(min) and % usage \> 4 hours Secondary outcome are access sleepiness and quality of sleep by questionnaire (ESS and PSQI) in Thai version, the correlation between wearable-derived and CPAP data: Total sleep time(min), sleep stage (light, deep and REM), and health information: heart rate, oxygen saturation, stress, sleep score and step counting If there is a comparison group: Researchers will compare wearable group and control group to see the effect of wearable to increase adherence of CPAP used. Participants will * Divide into two group by randomization using 4 block randomization * In wearable group, the participants will receive wearable and download application, they allow to access all the time * In control group, the participants will receive wearable and download application, but they will not allow to access until they come to hospital for follow up at the end of the study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea (OSA)

Currently open trials in the same condition.

NCT07292922 — Digital-supported Orofacial Myofunctional Therapy in OSA · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
NCT07103941 — IOA Preventing Occlusal Changes With MAD Use · NA · recruiting
NCT07121452 — Telehealth for Sleep Apnea: Effectiveness, Implementation, and Cost in the Military Health System · NA · recruiting

Other Ramathibodi Hospital trials

Trials by the same sponsor.

NCT07533604 — SnapDandCGMinType2Diabetes · NA · recruiting
NCT06983886 — The Effect of Local Infiltration of Tranexamic Acid on Postoperative Blood Loss in Orthognathic Surgery · Phase 1, PHASE2 · not yet recruiting
NCT06965088 — Comparison of Recurrence Rate of Keloid After Excision Between Intra-operative Steroid Injection and Steroid With Platel · Phase 2 · active not recruiting
NCT06453603 — Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome · NA · not yet recruiting
NCT06176703 — Mobile Application for Self-Management of Type 2 Diabetes Mellitus · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07377968 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ramathibodi Hospital
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07377968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing